Table 1 Characteristics of our series of 2493 patients
Features | |
|---|---|
Follow-up, months | |
Mean (SD) | 56 (36) |
Median (Min-Max) | 50 (4–159) |
FU ≥ 2-yy, no (%) | 2018 (81 %) |
FU ≥ 5-yy, no (%) | 982 (39 %) |
FU ≥ 7-yy, no (%) | 481 (19 %) |
FU ≥ 10-yy, no (%) | 179 (7 %) |
Age, yr | |
Mean (SD) | 71.7 (5.9) |
Median (Min-Max) | 73 (43–86) |
PSA, ng/ml | |
Mean (SD) | 15.0 (26.0) |
Median (Min-Max) | 8.6 (0.39-749) |
Tumor Stage, % | |
cT1 | 30.5 % |
cT2 | 57.5 % |
cT3-4 | 12 % |
Bone Scan staging | |
Performed | 67 % |
Not performed | 33 % |
Abdominal CT staging | |
Performed | 59 % |
Not performed | 41 % |
Endo-coil or pelvic MRI staging | |
Performed | 15 % |
Not performed | 85 % |
TRUS | |
Performed | 49 % |
Not performed | 51 % |
Biopsic Gleason Score, % | |
≤6 | 48 % |
3 + 4 | 22 % |
4 + 3 | 11.5 % |
8 | 12 % |
9-10 | 6.5 % |
D’Amico Risk Classification, % | |
Low | 21.5 % |
Intermediate | 32 % |
High | 46.5 % |
Biopsy cores sampled, no | |
Mean (SD) | 10.3 (4.2) |
Median (Min-Max) | 10 (2–42) |
% Positive Cores, % | |
Mean (SD) | 44.3 % (28.0 %) |
Median (Min-Max) | 40 % (3-100 %) |
RT Dose, ED2Gy | |
Mean (SD) | 75.5 (3.0) |
Median (Min-Max) | 76.0 (67.1-81.1) |
RT alone, % | 38 % |
RT plus ADT, % | 62 % |